



DEMOGRAPHY Q&A



DISCLAIMER


The preceding has been presented for informational purposes only. None of the information contained herein constitutes an offer to sell, or a solicitation of an offer to buy any security or investment vehicle, nor does it constitute an investment recommendation or legal, tax, accounting or investment advice by Hedgeye or any of its employees, officers, agents or guests. This information is presented without regard for individual investment preferences or risk parameters and is general, non-tailored, non-specific information. This content is based on information from sources believed to be reliable. Hedgeye is not responsible for errors, inaccuracies or omissions of information. The opinions and conclusions contained in this report are those of the individual expressing those opinions or conclusion and are intended solely for the use of Hedgeye's subscribers and the authorized recipients of the content. All investments entail a certain degree of risk and financial instrument prices can fluctuate based on several factors, including those not considered in the preparation of the content. Consult your financial professional before investing.

TERMS OF USE


The information contained herein is protected by United States and foreign copyright laws and is intended solely for the use of its authorized recipient. Access must be provided directly by Hedgeye.

Redistribution or republication is strictly prohibited. For more detail please refer to the Terms of Service at https://www.hedgeye.com/terms_of_service.


2020 GENERAL FERTILITY




2020 CENSUS RESULTS



2020 CENSUS RESULTS





2020 CENSUS RESULTS


The 10 Fastest-Growing Metro Areas in 2020 Change in population, July 1, 2019, to July 1, 2020. Austin-Round Rock-Georgetown, Texas 3.0% 2.7% Boise City, Idaho 2.7% Lakeland-Winter Haven, Fla. 2.4% Fayetteville-Springdale-Rogers, Ark. Cape Coral-Fort Myers, Fla. 2.4% Provo-Orem, Utah 2.4% Phoenix-Mesa-Chandler, Ariz. 2.1% Raleigh-Cary, N.C. 2.0% North Port-Sarasota-Bradenton, Fla. 2.0% Charleston-North Charleston, S.C. 1.8% Among metros with at least 500,000 people on July 1, 2019.

The 10 Metro Areas That Shrank the Most	
Change in population, July 1, 2019, to July	1, 2020.
Jackson, Miss.	-1.0%
Urban Honolulu	-1.0%
San Jose-Sunnyvale-Santa Clara	-0.7%
Youngstown-Warren, Ohio-Pa.	-0.6%
San Francisco-Oakland	-0.6%
New York-Newark, N.YN.JPa.	-0.6%
L.ALong Beach-Anaheim	-0.6%
Chicago, IIIIndWis.	-0.5%
Syracuse, N.Y.	-0.4%
Pittsburgh	-0.4%
Among metros with at least 500,000 people on July 1, 2019 Source: Census annual population estimates • By The New York Times	

Source: Census annual population estimates . By The New York Times


SOUTH/WEST GROWING... NE/MIDWEST NOT

Total Population, YoY Growth Rate by Region, 2000-2019




REAL PERSONAL INCOME

Real Personal Income By Census Region, Index to US Average = 100.




LIFE EXPECTANCY IN <u>6TH YEAR</u> OF DECLINE

US Life Expectancy, 2010-2020




TREND: LIFE EXPECTANCY BY AGE




TREND: LIFE EXPECTANCY BY AGE

Age-Specific Death Rates, 2018-2019




GEN-X V. MILLENNIALS




CANCER IN THE YOUNG

Age-Specific Annual % Change in Incidence of Colon + Rectum Cancer




Breast Cancer Rate of Mortality and Incidence



General Studies of Long-Term Symptoms


How long do C19 symptoms last? Not an easy question to answer, since most studies (a) focus on acute symptoms and (b) don't emphasize long-term follow up.


- Best-known study was conducted through the "Covid Symptom Study App," run <u>by</u> <u>health-science company Zoe with King's</u> <u>College London and Massachusetts General</u> <u>Hospital</u>. 4,182 users who tested positive logged symptoms prospectively. Results, in days after positive test (see chart on right):
 - 65% "return to previous level of health" in 14-21 days
 - 10% are after 21 days
 - 4.5% are sick after 56 days
 - 2.3% are sick after 84 days





Data from the COVID Symptom Study suggests that one in ten people still have COVID-19 symptoms after three weeks

- <u>Better controlled (and retrospective) study</u> was conducted on Apr to Sep 2020 by research institutes in San Mateo
 CA and Reno NV on 233 cases (only 8 hospitalized) versus 3,652 negative controls and 17,474 nontested controls.
 Results:
 - 42% have at least one symptom after 30 days
 - 34% have at least one symptom after 60 days
 - 24% have at least one symptom after 90 days
- Additional conclusions of the CA/NV study:
 - C19 patients who have >5 initial symptoms, especially dyspnea, are more likely to suffer long-term symptoms than those with fewer initial symptoms.
 - ❖ of those with more symptoms, 41% still with symptoms at 90 days
 - ❖ of those with fewer, 3% still with symptoms at 90 days
 - For new diagnoses/procedures, biggest relative incidence gap between C19 patients and controls were:
 - ❖ 1st: lung damage
 - ❖ 2nd: blood clots
 - ❖ 3rd: heart damage, heart failure, kidney damage










6-MINUTE WALKING DISTANCE

Avg. Meters: Hong Kong SARS Survivors Minus Control Group, at 24 Months After Illness



LONG-TERM EFFECTS OF C19: PHYSIOLOGY

<u>Specific Studies of Long-Term Organ or Syndrome Effects</u>. C19 has aptly been called a "<u>multi-organ disease</u>." Long-term symptoms result from long-term injury to dysfunction of organ systems.

- <u>Lungs/Respiratory</u>. Regardless of symptoms, <u>highest single confirmed organ injury rate</u>. Post-hospitalization, <u>well over 50% of C19 patients show some combination</u> of lung scarring (by CT), reduced lung capacity, reduced 02 diffusion capacity, reduced expiratory volume, etc. Single most serious chronic C19 complaint is difficulty breathing (dyspnea).
- Heart/Cardiovascular. On examination, high share of post-19 patients show changes to blood (dyslipidemia, typically excess lypids) or <u>fluctuating blood pressure</u>. There is raised incidence of <u>systemic clotting and thrombosis</u>. In German post-hospital study, <u>78% had cardiovascular abnormalities</u>; 60% had myocarditis (injury to heart muscle); many had reduced left ventricle ejection fraction.
- o <u>Brain/Neurological</u>. Neurologic problems are common in acute C19: <u>43% at onset; 63% at hospitalization;</u> <u>82% at some point in disease</u>. These include myalgias (45%); headaches (38%), encephalopathy (32%), dizziness (30%) and frequent loss of smell or taste. (Northwestern study.) At an avg 111 days after hospitalization, patients report <u>memory loss</u> (34%), <u>sleep disorders</u> (31%), and <u>concentration loss</u> (28%). (French study.) "Brain fog"—including slow reaction and difficulty problem-solving—could have multiple causes, from (worst) ministrokes to (best) raised serum CRP levels. (Zhejiang University study).


LONG-TERM EFFECTS OF C19: PHYSIOLOGY


- <u>Mental Health/Malaise</u>: CFS/ME or Chronic Fatigue Syndrome/Encephalomyelitis—or "<u>post-viral</u> <u>syndrome</u>"—is the single longest-lasting symptom of C19. Often linked to depression or (in extreme instances) PTSD. Closely related to confusion and "brain fog." Cause: Most likely, <u>raised CRP and hyperactive immune system</u> (hence "post viral"). It could also be caused by <u>neurological injury</u>.
- o <u>Kidney/Renal</u>: AKI or Acute Kidney Injury is <u>now recognized as a "common" complication of C19</u>. Prevalence in hospitalized patients estimated at >20%; in ICU patients, >50%. No estimate in all C19 patients.
- o <u>Other Long-Term Organ Injury</u>: <u>Digestive illness</u> is a frequent acute complication which can be longer-term (e.g., loss of appetite). <u>Skin/Dermatology</u> is another (e.g., swelling, rashes, spotting, hair loss).

Bottomline: Rather than measure the long-term cost of C19 in terms of mortality, maybe we should measure it in terms of chronic disability. That may multiply the number affected by X50. Consider SARS, a related coronavirus which infected 8,019 people in 2003, killing 900. 17 years later, in just those 8K people, SARS is still generating just about every one of the long-term sequelae that we're now discovering in C19: From lung damage and lipid disorders to PTSD, chronic inflammation and fatigue, and abnormally slow walking speed.

Nicholas Hart, the British physician who treated Prime Minister Boris Johnson, calls C19 "this generation's polio"--a disease that could leave many marked by its scars and reshape global health care.

FENTANYL





United States, Sep 2020, Opioids (T40.0-T40.4,T40.6)

Reported number of deaths: 64,472
Predicted number of deaths: 66,813
Percent pending investigation: 0.25
Percent with drugs specified: 94.2

United States, Sep 2020,
Synthetic opioids, excl. methadone (T40.4)
Reported number of deaths: 52,157
Predicted number of deaths: 53,877
Percent pending investigation: 0.25
Percent with drugs specified: 94.2

FENTANYL

The Gupta (Red) and Siegfried (Blue) Method of Synthesizing Fentanyl

